- Indivior PLC ADR press release (OTCPK:INVVY): Q2 Non-GAAP EPS of $0.06.
- Revenue of $221M (+10.0% Y/Y).
- Outlook: Total FY 2022 expected NR range maintained at $840M to $900M (+10% vs. FY 2021 at the mid-point); Adjusted gross margin expected to be in the low- to mid-80% range (unchanged vs. prior guidance), reflecting higher cost inflation and the relative share resilience of SUBOXONE Film in the first half of 2022; Adjusted SG&A expected to be in the range of $440M to $455M (unchanged vs. prior guidance), primarily reflecting the annualization of growth investments behind SUBLOCADE and PERSERIS and costs related to the US listing; R&D expected to be in the range of $80M to $85M (unchanged vs. prior guidance), primarily reflecting additional SUBLOCADE lifecycle management studies, SUBLOCADE manufacturing capacity expansion and early-stage asset advancement; phasing of these activities is expected to result in higher R&D expenditures in the second half of 2022 versus the first half of 2022; Adjusted operating income expected to be broadly similar to FY 2021’s adjusted operating income of $187m (unchanged vs. prior guidance).